CHEK1 and triple-negative breast carcinoma: RNAi studies have identified neuroblastoma [20] and Fanconi’s Anemia [18] whilst small molecule inhibitor studies have revealed triple-negative breast cancer [24] and an Eμ-myc driven model of lymphoma as potential clinical targets of Chk1 inhibitor therapy [25,26].